Active: Liver Int Clear all

GWAS 2021-07-26

A Genome-Wide Association Study Identifying SVEP1 Variant as a Predictor of Response to Tolvaptan for Cirrhotic Ascites.

Kawaratani H, Sawai H et al.

Liver Int

Background & aims: Tolvaptan, vasopressin V2-receptor antagonist, has been used for patients wit...

Response to tolvaptan in hepatic ascites (body weight gain)

Replicated

413

Participants

N/A

Studies

Details PubMed

GWAS 2019-12-09

Genetic variants that associate with liver cirrhosis have pleiotropic effects on human traits.

Chen VL, Chen Y et al.

Liver Int

Background and aims: Cirrhosis is characterized by extensive fibrosis of the liver and is a major ca...

Cirrhosis

Replicated

440182

Participants

N/A

Studies

Details PubMed

GWAS 2019-06-17

A genome-wide association study in low susceptibility to hepatitis C virus infection (GEHEP012 Study).

Real LM, Fernández-Fuertes M et al.

Liver Int

A low proportion of individuals repeatedly exposed to the hepatitis C virus (HCV) remain uninfected....

Low susceptibility to hepatitis C infection

831

Participants

N/A

Studies

Details PubMed

Title

Author

Journal

Disease/Trait

Date

Actions

A Genome-Wide Association Study Identifying SVEP1 Variant as a Predictor of Response to Tolvaptan for Cirrhotic Ascites.

Kawaratani H, Sawai H et al.

Liver Int

Response to tolvaptan in hepatic ascites (body weight gain)

2021-07-26

Genetic variants that associate with liver cirrhosis have pleiotropic effects on human traits.

Chen VL, Chen Y et al.

Liver Int

Cirrhosis

2019-12-09

A genome-wide association study in low susceptibility to hepatitis C virus infection (GEHEP012 Study).

Real LM, Fernández-Fuertes M et al.

Liver Int

Low susceptibility to hepatitis C infection

2019-06-17